Kura Oncology, INC 8-K filings

Kura Oncology announced robust second quarter 2026 financial results, highlighted by significant revenue growth for KOMZIFTI and promising clinical updates for its pipeline assets.

Kura Oncology has amended executive employment agreements, modifying severance provisions for key officers in the event of termination or corporate transactions.

Kura Oncology announced its fourth quarter and full year 2025 financial results, highlighting the successful early commercial launch of KOMZIFTI and significant progress in its AML and solid tumor pipelines.

Kura Oncology, Inc. has adopted amended and restated bylaws, effective January 28, 2026, introducing significant changes to corporate governance, stockholder meeting procedures, and director indemnification.

Kura Oncology announced preliminary KOMZIFTI revenue of $2.1 million for its initial commercial period and detailed key development milestones for 2026.

Kura Oncology announced the first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from Kyowa Kirin.

Kura Oncology and Kyowa Kirin announced full FDA approval for KOMZIFTI (ziftomenib) as the first and only oral menin inhibitor for relapsed or refractory NPM1-mutated AML.

Kura Oncology reported Q3 2025 financial results, highlighting accelerated progress in its ziftomenib AML program and a strong cash position bolstered by collaboration payments.

Kura Oncology, Inc. announced the receipt of a $30 million milestone payment from Kyowa Kirin following the dosing of the first patient in its KOMET-017 Phase 3 trials for ziftomenib.

Kura Oncology, Inc. amended its 2023 Inducement Option Plan to reserve an additional 750,000 shares, bringing the total to 3,250,000 shares, to attract new talent.

Kura Oncology reports Q2 2025 financial results, highlights FDA Priority Review for ziftomenib in R/R NPM1-m AML with a November 30, 2025 PDUFA date, and outlines commercialization readiness.

Kura Oncology, Inc. has entered into a Co-Promotion and Medical Affairs Agreement with Kyowa Kirin, Inc. to jointly commercialize its lead product candidate, ziftomenib, for acute myeloid leukemia and other hematologic malignancies in the United States.

Kura Oncology, Inc. announced positive updated clinical data from its KOMET-007 Phase 1a/1b trial of ziftomenib in combination with standard chemotherapy for newly diagnosed acute myeloid leukemia, demonstrating high remission rates and supporting advancement to Phase 3 studies.

Kura Oncology, Inc. announced that its stockholders approved an increase of 4.75 million shares to its 2014 Equity Incentive Plan and re-elected three Class II directors at its Annual Meeting held on June 5, 2025.

Kura Oncology announced that the FDA has accepted its New Drug Application for ziftomenib for relapsed/refractory acute myeloid leukemia with an NPM1 mutation, granting it Priority Review with a target action date of November 30, 2025, following positive pivotal Phase 2 KOMET-001 trial results.

Kura Oncology announces Q1 2025 financial results, highlighted by the NDA submission for ziftomenib and a $45 million milestone payment.

Kura Oncology reports positive topline results from its ziftomenib trial in R/R NPM1-mutant AML, anticipates NDA submission, and highlights a strategic collaboration with Kyowa Kirin.

Kura Oncology and Kyowa Kirin announce positive topline results from the KOMET-001 trial and plans to initiate Phase 3 trials for ziftomenib in AML, with an NDA submission expected in Q2 2025.

Kura Oncology has entered into a lease agreement for a new office and lab space in San Diego, signaling growth and continued investment in research and development.

Kura Oncology's Chief Medical Officer, Stephen Dale, has resigned due to personal health reasons, with the company appointing Mollie Leoni as the new Chief Medical Officer and Francis Burrows as Chief Scientific Officer.

Kura Oncology has increased its stock option pool by 1.9 million shares to attract new employees, bringing the total to 2.5 million shares.

Kura Oncology and Kyowa Kirin have entered into a collaboration and license agreement to develop and commercialize Kura's ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies globally.

Kura Oncology reported its third quarter 2024 financial results, highlighted by progress in clinical trials and a strong cash position.

Kura Oncology has appointed Michael J. Vasconcelles, M.D. to its Board of Directors and Compensation Committee, effective September 13, 2024.

Kura Oncology reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a pivotal trial and a Breakthrough Therapy Designation for ziftomenib.

Kura Oncology's stockholders approved an amendment to the 2014 Equity Incentive Plan, increasing the number of shares available for issuance, and elected two Class I directors at their annual meeting on June 5, 2024.

Kura Oncology has completed enrollment of 85 patients in the Phase 2 portion of its KOMET-001 trial for ziftomenib in relapsed or refractory NPM1-mutant acute myeloid leukemia, with topline data expected in early 2025.

Kura Oncology announced first quarter 2024 financial results, highlighted by a Breakthrough Therapy Designation for ziftomenib and a strong cash position of $527 million.

Kura Oncology announced positive preliminary data from its ziftomenib combination trials, along with a strong cash position extending into 2027.

Kura Oncology reports promising early clinical results for ziftomenib in combination with standard therapies for AML, alongside a successful $146 million private placement, extending their cash runway into 2027.